Instructions
Dismiss this Message

Scancell Holdings Share Chat (SCLP)

Post a Message Filter

Load newer
Today 19:04Price: 10.25
botski834 posts
RE: Nom

Completely agree about WF.
No Opinion
Reply to post
Today 18:51Price: 10.25
KonarA1,597 posts
RE: Nom

Well done on 10k.

Wildforce is without doubt the poster i respect the most. Knowledgeable and well read on the subject, and always manages to stay above any nonsense.

I have definitely benefited immensely from the 10k posts.
No Opinion
Reply to post
Today 17:32Price: 10.25
CHELSEA733,196 posts
RE: Nom

Interesting conversation guys, itching to hear how we are progressing, which I"m pretty sure will take up a fair bit of the AGM and subsequent Proactive presentation.

Wild, wanted to congratulate you on reaching 10,000 posts, we are all the wiser for it.

Take Care, have a good weekend.
No Opinion
Reply to post
Today 17:17Price: 10.25
Wildforce10,000 posts
RE: Nom

Yes, interesting and does highlight that a few extra months is seen as a success but ... plenty of room for further improvement!

“””Among those who received the combination, the median survival was 21.3 months, compared with 17.6 months for those who received chemo alone. The difference was not statistically significant.
But when the researchers looked at women who had a marker called PD-L1 on their cancer cells, the results were striking: The median survival was 25 months in the combination group, versus 15.5 months with just chemo. That finding has not been analyzed statistically, and the patients are still being followed.””

Chester, no worries.

What’s interesting about the scib1 trial is that it observed an increase in pd-l1 on the tumour cells ... I.e. they try to ramp up their own protection as a result of an increase of t-cells trying to attack them !

It’s all very interesting stuff !!

Take care all ..
Strong Buy
Reply to post
Today 16:11Price: 10.25
nomlungu1,886 posts
NYT article - Genentech

An interesting article on the NYT:

https://www.nytimes.com/2018/10/20/health/breast-cancer-immunotherapy.html
No Opinion
Reply to post
Today 15:25Price: 10.25
TorquayFan5,130 posts
Gooosed . .

This tweet - not sure I agree with it altogether but good to see awareness around :-

hTTps://twitter.com/BernardAFox/status/1053558541800407040

Great posts everybody today - WF, Botski, Chester, V V, RP, Hims.

Hope this jolly link works - otherwise - you know where. GLA
Strong Buy
Reply to post
Today 14:51Price: 10.25
RayPointer325 posts
RE: Listen to the prof !

VanVan

Scib1 has already gone through a very successful phase1/2 trial without a CI. So the combo trial with the CI Keytruda should be very interesting. Merck, the makers of Keytruda have said recently that they are still awaiting a successful combo trial despite many attempts by many companies.

In addition, scib1 has already been shown to have a memory affect in humans. This is the immune process that creates long living memory tcells that are instrumental in the immune system mounting attacks should the tumors reappear. So the body can defend itself against the cancer without further application of Scib1. These memory tcells can live for up to 10 years.
CIs do not have this memory capability
No Opinion
Reply to post
Today 14:23Price: 10.25
VanVan973 posts
RE: Listen to the prof !

Thanks Chester. Much appreciated
No Opinion
Reply to post
Today 14:05Price: 10.25
chester1873 posts
RE: Vanvan

Sorry Wildforce

Our messages have crossed.
The problem with typing on the phone and trying to keep an eye on the match

Chester
Strong Buy
Reply to post
Today 14:03Price: 10.25
chester1873 posts
RE: Listen to the prof !

VanVan

Through genetic mutations cancer cells gain the ability to hide in plain site from our own killer T-Cells. Checkpoint Inhibitors take the brakes off the Immune System which in simple terms makes the T Cells much more sensitive and able to attack the cancer cells.
Problem is that this can cause toxicity as the T Cells can then wrongly target our own healthy cells. Also, the CI's only work in 30% of people so how do you improve on the effectiveness?
The combination trials that are currently in vogue are investigating chemo-therapy and CI's to both weaken the cancer and attack with the immune system 'brakes-off'.
As can expect the toxicity is greatly increased but holy grail is a combi that works in say 60% of people.
So when a stand alone Modi 1 is shown to improve the percentage to 60% + and without the toxicity it will be the game changer.
The value of Checkpoint Inhibitor Treatments is currently over £100 Billion a year.
That's why it is so amazing to follow, study and be a small part of Scancell's journey.

I hope that adds a little more to your growing understanding of Scancell's potential.

ATB. Chester
Strong Buy
Reply to post
Load more